Eye care

B+L also plans by March 1 to start distributing its Blink dry eye drop line extension, Triple Care preservative free, and in the first half of the year to file an NDA in US for a Luxe formulation of its Lumify redness eye drop brand.

Returning to full Clear Eyes production and distribution and brand’s previous revenue levels aren’t expected within PCH’s current fiscal year, which ends in March; additional marketing spend expected.

Deal Snapshot: Eli Lilly has become increasingly interested in genetic treatments for the eye and has secured the rights to a high-profile gene therapy for a rare form of childhood blindness.

The biotech's C1q inhibitor, vonaprument, preserved vision but missed the primary Phase II endpoint on lesion growth. The stakes are high for a Phase III with a different primary endpoint.

Overseeing the diverse EMEA region as the regional president of Johnson & Johnson’s Vision business has been a whirlwind of activity for Jacqueline Henderson, in her role since 2023. Fresh back from the ESCRS 2024 meeting, she spoke to In Vivo about how J&J responds to market needs.